AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it will host a key opinion leader (KOL) meeting focused on pathological Tau protein as a therapeutic target and diagnostic biomarker for Alzheimer’s and other neurodegenerative diseases. The event will take place in New York City on Wednesday, November 6, 2019.